Integra LifeSciences (NASDAQ:IART) Hits New 52-Week High – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price reached a new 52-week high on Thursday . The stock traded as high as $16.50 and last traded at $16.3890, with a volume of 676230 shares traded. The stock had previously closed at $15.19.

Analyst Ratings Changes

IART has been the subject of several research reports. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Argus reaffirmed a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and increased their price objective for the company from $11.00 to $16.00 in a report on Thursday. Wells Fargo & Company lifted their target price on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Price Performance

The firm has a 50-day simple moving average of $11.76 and a two-hundred day simple moving average of $11.84. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -2.48, a P/E/G ratio of 1.14 and a beta of 1.08. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. The business had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts predict that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rubric Capital Management LP lifted its stake in shares of Integra LifeSciences by 58.4% in the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock valued at $90,233,000 after purchasing an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY increased its holdings in Integra LifeSciences by 50.6% in the first quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after buying an additional 1,347,700 shares in the last quarter. Bank of America Corp DE raised its position in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after acquiring an additional 589,408 shares during the period. Invenomic Capital Management LP raised its position in shares of Integra LifeSciences by 78.3% in the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after acquiring an additional 463,729 shares during the period. Finally, Kotler Kevin purchased a new stake in shares of Integra LifeSciences during the 4th quarter worth about $5,309,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.